The synergistic therapeutic effect of hepatocyte growth factor and granulocyte colony-stimulating factor on pulmonary hypertension in rats

被引:0
作者
Yinghua Guo
Longxiang Su
Yinghui Li
Na Guo
Lixin Xie
Dong Zhang
Xiaojun Zhang
Hongxia Li
Guizhi Zhang
Yajuan Wang
Changting Liu
机构
[1] Chinese PLA General Hospital,Nanlou Respiratory Disease Department
[2] Chinese PLA Postgraduate Medical School,Medical School
[3] Nankai University,State Key Laboratory of Space Medicine Fundamentals and Application
[4] Chinese Astronaut Research and Training Center,Respiratory Disease Department
[5] Chinese PLA General Hospital,undefined
来源
Heart and Vessels | 2014年 / 29卷
关键词
Pulmonary arterial hypertension; Hepatocyte growth factor; Granulocyte colony-stimulating factor; Bone marrow mesenchymal stem cells;
D O I
暂无
中图分类号
学科分类号
摘要
Pulmonary arterial hypertension (PAH) is characterized by a progressive increase in pulmonary arterial pressure and vascular resistance. Despite advances in therapy for PAH, its treatment and prognosis remain poor. We aimed to investigate whether the transplantation of bone marrow mesenchymal stem cells (MSCs) overexpressing hepatocyte growth factor (HGF), alone or in combination with granulocyte colony-stimulating factor (G-CSF), attenuates the development of experimental monocrotaline (MCT)-induced PAH. Three weeks after MCT administration, rats were divided into the following groups: (1) untreated (PAH); (2) HGF treated; (3) MSCs administered; (4) HGF-MSCs treated; and (5) HGF-MSCs plus G-CSF treated. After 3 weeks, hemodynamic changes, histomorphology, and angiogenesis were evaluated. To elucidate the molecular mechanisms of vascular remodeling and angiogenesis, serum levels of transforming growth factor (TGF)-β and endothelin-1 (ET-1) were measured, and the gene and protein expression levels of vascular cell adhesion molecule-1 (VCAM-1) and matrix metalloproteinase-9 (MMP-9) were determined. Compared with the PAH, MSC, and G-CSF groups, the HGF and HGF+G-CSF groups exhibited significantly reduced right ventricular hypertrophy and mean pulmonary arterial pressure (P < 0.05). Histologically, vessel muscularization or thickening and collagen deposition were also significantly decreased (P < 0.05). The number of vessels in the HGF+G-CSF group was higher than that in the other groups (P < 0.05). The TGF-β and ET-1 concentrations in the plasma of pulmonary hypertensive rats were markedly lower in the HGF and HGF+G-CSF groups (P < 0.05). Furthermore, HGF induced the expression of VCAM-1, and HGF treatment together with G-CSF synergistically stimulated MMP-9 expression. Transplanted HGF-MSCs combined with G-CSF potentially offer synergistic therapeutic benefit for the treatment of PAH.
引用
收藏
页码:520 / 531
页数:11
相关论文
共 274 条
  • [1] Runo JR(2003)Primary pulmonary hypertension Lancet 361 1533-1544
  • [2] Loyd JE(1997)Primary pulmonary hypertension N Engl J Med 336 111-117
  • [3] Rubin LJ(1991)Survival in patients with primary pulmonary hypertension. Results from a national prospective registry Ann Intern Med 115 343-349
  • [4] D’Alonzo GE(1984)Primary pulmonary hypertension: natural history and the importance of thrombosis Circulation 70 580-587
  • [5] Barst RJ(2000)Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor Nat Med 6 698-702
  • [6] Ayres SM(2004)Endothelial dysfunction in pulmonary hypertension Circulation 109 159-165
  • [7] Bergofsky EH(2001)Genetic aspects of pulmonary arterial hypertension Ann Med 33 596-603
  • [8] Brundage BH(2004)Pathology of pulmonary hypertension Cardiol Clin 22 343-351
  • [9] Detre KM(2001)Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension FASEB J 15 427-438
  • [10] Fishman AP(2001)The pathobiology of pulmonary hypertension. Endothelium Clin Chest Med 22 405-418